Supernus Pharmaceuticals (SUPN) Stock: Buy, Sell, or Hold?
$29.56
+0.11 (+0.37%)
▲
5d:
+10.55%
30d:
-29.64%
90d:
-37.31%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 29, 2026
0d
Protect SUPN Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (91%)
Quality Score
52/100
Position
OVERSOLD
30-Day Fair Range
$31.46 – $43.71
Position: OVERSOLD
Forward P/E & Valuation
7.4x
CHEAP
vs 11.8x historical avg
Wall Street Target
$54.14
+83.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$25.92 / $44.31
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: SUPN shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When SUPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$63.94
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$39.70
25.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SUPN is currently trading at $29.56, which is considered oversold relative to its 30-day fair value range of $31.46 to $43.71. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.4) compared to its historical average (11.8). Remarkably, the market is currently pricing in an annual earnings decline of 14.5% over the next few years. This pessimistic expectation contrasts with the company's recent 239.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SUPN is in a downtrend. Immediate support is located at $25.92, while resistance sits at $44.31.
Market Sentiment: SUPN scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.14 (+83.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SUPN is in a downtrend. Immediate support is located at $25.92, while resistance sits at $44.31.
Market Sentiment: SUPN scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.14 (+83.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$31.46 -
$43.71
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$31.46 -
$43.71
Current vs Trading Range
OVERSOLD
Support Level
$25.92
Resistance Level
$44.31
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding SUPN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 83.8% below Wall St target ($54.14)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
7.36
Wall Street Target
$54.14
(+83.8%)
Revenue Growth (YoY)
13.4%
Earnings Growth (YoY)
239.4%
Profit Margin
32.8%
Valuation Discount vs History
-14.5% cheaper
PE vs Historical
7.4 vs 11.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.5%
(market-implied from PE analysis)
1-Year Target
$26.50
(-10%)
2-Year Target
$23.85
(-19%)
3-Year Target
$21.47
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→12)
$34.44
(+17%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.5%)
$101.57
(+245%)
Base:
(SPY PE: 7.4, Growth: 8.5%)
$37.62
(+28%)
Bear:
(PE: 6.3, Growth: 8.5%)
$31.97
(+9%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.4 to 11.8
Stabilization Target:
$47.24
(+60.4%)
PE Expansion Potential:
+60.4%
Share SUPN Analysis
Share this live SUPN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SUPN)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 30, 2026
Daily AI digest
AI Retail Discussion Summary:
Supernus Pharmaceuticals reported strong Q3 earnings with record revenue and growing sales across its portfolio, particularly for Qelbree and ZURZUVAE. The company also announced the expected closing of its merger with Indivior Pharmaceuticals in November.
Key Retail Themes:
Revenue growth
Product portfolio expansion
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SUPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Advanced SUPN Option Strategies
Professional options setups generated by AI based on today's SUPN price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SUPN Research Pages
